BUSINESS

Fujifilm, Australian Startup Join Hands for Contract Manufacturing of iPS Cell-Derived Regenerative Medicine Products

October 1, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Fujifilm said on September 30 that it has entered into a basic agreement with Cynata Therapeutics to undertake the contract manufacturing of the Australian biotech’s iPS cell-derived regenerative medicine products. In line with this, the Japanese company will hand back…

To read the full story

Fujifilm Grabs Rights to Cynata’s Cell Therapy for GVHD
September 18, 2019

BUSINESS

Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
Asahi Kasei Nabs Japan Rights to Additional Empaveli Indications
July 1, 2026
Viatris Eyes Japan Filing This Year for IgAN Drug
July 1, 2026
Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…